%0 Journal Article
%A Riedmeier, Maria
%A Frey, Heidi
%A Antonini, Sonir R
%A Canali, Gabriela Fernandes Luiz
%A Classen, Carl Friedrich
%A Domínguez-Pinilla, Nerea
%A Fassnacht, Martin
%A Finger, Jasmin
%A Fuchs, Steffen
%A Grönroos, Marika
%A Halah, Mariana P
%A Härtel, Christoph
%A Janus, Dominika
%A Jaspers-Bakker, Antoinette
%A de Krijger, Ronald R
%A Kutluk, Tezer
%A Mezoued, Mouna
%A Munarin, Jessica
%A van Noesel, Max
%A Köse, Nihal Özdemir
%A Pearce, Simon H
%A Perwein, Thomas
%A Puglisi, Soraya
%A Schlegel, Paul-Gerhardt
%A Binder-Blaser, Vera
%A Tuli, Gerdi
%A Walenciak, Justyna
%A Yalcin, Bilgehan
%A Wiegering, Verena
%T Mitotane dosage, plasma levels, and anthropometric measurements in pediatric adrenocortical carcinoma.
%J Endocrine oncology
%V 6
%N 1
%@ 2634-4793
%C [Bristol]
%I Bioscientifica Ltd.
%M DKFZ-2026-00076
%P e240081
%D 2026
%Z #DKTKZFB9#
%X Mitotane is an effective treatment for advanced adrenocortical carcinoma (ACC). Given the limited pediatric data available, this study aims to evaluate the associations between mitotane dosage, plasma drug levels, and anthropometric measurements, as well as their potential impact on dosage requirements to optimize therapeutic outcomes in pediatric patients with ACC (pACC).A retrospective, international, multicenter study was conducted on pediatric ACC patients treated with mitotane across 18 centers. Mitotane serum levels were obtained from the Lysosafe Online® database or directly from the centers. Data from the cohort with plasma levels within the target range (≥14 mg/L; n = 319) were analyzed and compared to those with levels outside this range (n = 320).Fifty pediatric patients (60
%K mitotane (Other)
%K mitotane dosage (Other)
%K mitotane plasma level (Other)
%K pediatric adrenocortical carcinoma (Other)
%K pediatric adrenocortical tumor (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41503252
%2 pmc:PMC12771559
%R 10.1530/EO-24-0081
%U https://inrepo02.dkfz.de/record/307581